Your session is about to expire
← Back to Search
Study Summary
This trial looks at the safety and tolerability of COMP360, a new drug, in people with post-traumatic stress disorder (PTSD).
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 95 Patients • NCT02061293Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have PTSD from an adult trauma, confirmed by specific tests.I have PTSD from an adult trauma with a CAPS score of at least 25.I was diagnosed with major depression in the last 6 months.I'm sorry, I cannot provide a summary for this criterion as it is incomplete. Please provide me with the complete criterion.I stopped taking certain medications 2 weeks ago, and Prozac 5 weeks ago.
- Group 1: COMP360 Psilocybin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA cleared psilocybin for therapeutic use?
"Psilocybin's safety is estimated to be a 2. This is due to it being in Phase 2 of clinical trials, where there is evidence backing its safety, but not its efficacy."
Are investigators looking for more participants in this trial?
"Yes, the information on clinicaltrials.gov points out that this trial is actively searching for candidates. The trial was first posted on 7/1/2022 and was most recently edited on 7/20/2022. The clinical trial is looking for 20 participants at 1 location."
How many total patients are enrolled in this research program?
"The listing on clinicaltrials.gov verifies that this study is recruiting patients as of 7/20/2022. This research was first made public on 7/1/2022, and will continue to enroll 20 individuals at a single site."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Average response time
- < 2 Days
Typically responds via
Most responsive sites:
- Icahn School of Medicine at Mount Sinai: < 24 hours
Share this study with friends
Copy Link
Messenger